MGRX vs MRK
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
MGRX exhibits severe financial distress, highlighted by a critical Piotroski F-Score of 1/9 and a catastrophic operating margin of -1576.40%. Despite a low Price-to-Book ratio of 0.35, the company is experiencing consistent revenue contraction (-10.30% YoY) and massive long-term value destruction, with a 5-year price decline of 99.3%. The lack of analyst coverage and bearish insider activity further signal a lack of confidence in the company's viability.
MRK shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
MGRX vs MRK: Head-to-Head Comparison
This page compares Mangoceuticals, Inc. (MGRX) and Merck & Co., Inc. (MRK) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.